Clinical trial

Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)

NCT01160094

Study summary

ClinicalTrials.gov

Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Treatment Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2010-02-01

PhaseN/A

Conditions

Cancerverified · MONDO: cancer

Interventions

TreatmentDRUG

Sponsors & collaborators

Novartislead sponsor

Mapped research locations

JeddahSaudi Arabia3 BogotáColombia1 RiyadhSaudi Arabia1 MedellínColombia1 BucaramangaColombia1 DammamSaudi Arabia1 PereiraColombia1 PastoColombia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01160094 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.